Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Non Operating Income (2019 - 2025)

Rein Therapeutics (RNTX) has disclosed Non Operating Income for 7 consecutive years, with -$68000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 83.54% to -$68000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$345000.0 through Sep 2025, down 194.78% year-over-year, with the annual reading at $544000.0 for FY2023, 71.07% up from the prior year.
  • Non Operating Income for Q4 2025 was -$68000.0 at Rein Therapeutics, up from -$89000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $336000.0 in Q4 2022, with the low at -$413000.0 in Q4 2024.
  • Average Non Operating Income over 5 years is $72388.9, with a median of $81500.0 recorded in 2021.
  • The sharpest move saw Non Operating Income skyrocketed 3800.0% in 2023, then crashed 742.86% in 2024.
  • Over 5 years, Non Operating Income stood at $71000.0 in 2021, then skyrocketed by 373.24% to $336000.0 in 2022, then tumbled by 114.58% to -$49000.0 in 2023, then plummeted by 742.86% to -$413000.0 in 2024, then skyrocketed by 83.54% to -$68000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$68000.0, -$89000.0, and $49000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.